146 related articles for article (PubMed ID: 35810463)
1. Quantification-Promoted Discovery of Glycosylated Exosomal PD-L1 as a Potential Tumor Biomarker.
Zhu L; Xu Y; Kang S; Lin B; Zhang C; You Z; Lin H; Yang C; Song Y
Small Methods; 2022 Sep; 6(9):e2200549. PubMed ID: 35810463
[TBL] [Abstract][Full Text] [Related]
2. Homogeneous, Low-volume, Efficient, and Sensitive Quantitation of Circulating Exosomal PD-L1 for Cancer Diagnosis and Immunotherapy Response Prediction.
Huang M; Yang J; Wang T; Song J; Xia J; Wu L; Wang W; Wu Q; Zhu Z; Song Y; Yang C
Angew Chem Int Ed Engl; 2020 Mar; 59(12):4800-4805. PubMed ID: 31912940
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of serum-derived exosomal PD-L1 expression in patients with advanced pancreatic cancer.
Park SJ; Park JY; Shin K; Hong TH; Lee M; Kim Y; Kim IH
BMC Cancer; 2023 May; 23(1):389. PubMed ID: 37127565
[TBL] [Abstract][Full Text] [Related]
4. Coupling Aptamer-based Protein Tagging with Metabolic Glycan Labeling for In Situ Visualization and Biological Function Study of Exosomal Protein-Specific Glycosylation.
Zhu L; Xu Y; Wei X; Lin H; Huang M; Lin B; Song Y; Yang C
Angew Chem Int Ed Engl; 2021 Aug; 60(33):18111-18115. PubMed ID: 34043264
[TBL] [Abstract][Full Text] [Related]
5. Tracing Tumor-Derived Exosomal PD-L1 by Dual-Aptamer Activated Proximity-Induced Droplet Digital PCR.
Lin B; Tian T; Lu Y; Liu D; Huang M; Zhu L; Zhu Z; Song Y; Yang C
Angew Chem Int Ed Engl; 2021 Mar; 60(14):7582-7586. PubMed ID: 33382182
[TBL] [Abstract][Full Text] [Related]
6. Exosomal PD-L1 in cancer and other fields: recent advances and perspectives.
Lu MM; Yang Y
Front Immunol; 2024; 15():1395332. PubMed ID: 38726017
[TBL] [Abstract][Full Text] [Related]
7. Circulating PD-L1 is associated with T cell infiltration and predicts prognosis in patients with CRLM following hepatic resection.
Chen X; Du Z; Huang M; Wang D; Fong WP; Liang J; Fan L; Wang Y; Yang H; Chen Z; Hu M; Xu R; Li Y
Cancer Immunol Immunother; 2022 Mar; 71(3):661-674. PubMed ID: 34322779
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy.
Shin K; Kim J; Park SJ; Lee MA; Park JM; Choi MG; Kang D; Song KY; Lee HH; Seo HS; Lee SH; Kim B; Kim O; Park J; Kang N; Kim IH
Sci Rep; 2023 Apr; 13(1):6952. PubMed ID: 37117200
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous detection of cancerous exosomal miRNA-21 and PD-L1 with a sensitive dual-cycling nanoprobe.
Qin X; Xiang Y; Li N; Wei B; Chen Y; Fang D; Fang M; Li Q; Liu J; Tang Y; Li X; Yang F
Biosens Bioelectron; 2022 Nov; 216():114636. PubMed ID: 35986985
[TBL] [Abstract][Full Text] [Related]
10. Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer.
Niu M; Liu Y; Yi M; Jiao D; Wu K
Front Immunol; 2022; 13():827921. PubMed ID: 35386715
[TBL] [Abstract][Full Text] [Related]
11. Proximity ligation assay mediated rolling circle amplification strategy for in situ amplified imaging of glycosylated PD-L1.
Fu Y; Qian H; Zhou X; Wu Y; Song L; Chen K; Bai D; Yang Y; Li J; Xie G
Anal Bioanal Chem; 2021 Nov; 413(28):6929-6939. PubMed ID: 34523014
[TBL] [Abstract][Full Text] [Related]
12. A magneto-activated nanoscale cytometry platform for molecular profiling of small extracellular vesicles.
Chen K; Duong BTV; Ahmed SU; Dhavarasa P; Wang Z; Labib M; Flynn C; Xu J; Zhang YY; Wang H; Yang X; Das J; Zargartalebi H; Ma Y; Kelley SO
Nat Commun; 2023 Sep; 14(1):5576. PubMed ID: 37696888
[TBL] [Abstract][Full Text] [Related]
13. Coaxial dual-path electrochemical biosensing and logic strategy-based detection of lung cancer-derived exosomal PD-L1.
Liu J; Liu Z; Zhao C; Jiao Y; Li B; Shi J; Chen Z; Zhang Z
Nanoscale; 2024 May; 16(18):8950-8959. PubMed ID: 38630023
[TBL] [Abstract][Full Text] [Related]
14. Isolation of circulating exosomes and identification of exosomal PD-L1 for predicting immunotherapy response.
Zhang J; Zhu Y; Guan M; Liu Y; Lv M; Zhang C; Zhang H; Zhang Z
Nanoscale; 2022 Jun; 14(25):8995-9003. PubMed ID: 35700522
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of circulating exosomal PD-L1 and soluble PD-L1 in extranodal NK/T-cell lymphoma, nasal-type.
Li JW; Wei P; Guo Y; Shi D; Yu BH; Su YF; Li XQ; Zhou XY
Am J Cancer Res; 2020; 10(12):4498-4512. PubMed ID: 33415014
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of GLT1D1 induces immunosuppression through glycosylation of PD-L1 and predicts poor prognosis in B-cell lymphoma.
Liu X; Zhang Y; Han Y; Lu W; Yang J; Tian J; Sun P; Yu T; Hu Y; Zhang H; Huang P; Liu P
Mol Oncol; 2020 May; 14(5):1028-1044. PubMed ID: 32157792
[TBL] [Abstract][Full Text] [Related]
17. ExoPD-L1: an assistant for tumor progression and potential diagnostic marker.
Hu R; Jahan MS; Tang L
Front Oncol; 2023; 13():1194180. PubMed ID: 37736550
[TBL] [Abstract][Full Text] [Related]
18.
Huang M; Zhu L; Kang S; Chen F; Wei X; Lin L; Chen X; Wang W; Zhu Z; Yang C; Song Y
Anal Chem; 2021 Dec; 93(48):15958-15963. PubMed ID: 34812034
[TBL] [Abstract][Full Text] [Related]
19. The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis.
Wang YN; Lee HH; Hsu JL; Yu D; Hung MC
J Biomed Sci; 2020 Jul; 27(1):77. PubMed ID: 32620165
[TBL] [Abstract][Full Text] [Related]
20. Exosomal PD-L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies.
Zhou K; Guo S; Li F; Sun Q; Liang G
Front Cell Dev Biol; 2020; 8():569219. PubMed ID: 33178688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
